The MD Anderson Cancer Center expert discussed the future of acute myeloid leukemia treatment, and how the field is evolving rapidly.
Courtney DiNardo, MD
Advertisement
Articles by Courtney DiNardo, MD
The MD Anderson Cancer Center expert discussed next steps in the evaluation of ivosenidib plus venetoclax, with or without azacytidine, in patients with IDH1-mutated acute myeloid leukemia.
The MD Anderson Cancer Center expert spoke about the efficacy of ivosenidib plus venetoclax, with or without azacytidine, in patients with IDH1-mutated acute myeloid leukemia.
At the 2020 ASCO Virtual Program, Courtney DiNardo, MD, presented on a study of the combination therapy consisting of ivosenidib plus venetoclax with or without azacytidine patients with IDH1-mutated acute myeloid leukemia.
The MD Anderson Cancer Center expert discussed why there is an unmet need for more treatments in patients with IDH1-mutated acute myeloid leukemia.
Advertisement
Latest Updated Articles
Courtney DiNardo, MD, on Study Methods Evaluating a Doublet, Triplet Regimens in AMLPublished: July 8th 2020 | Updated:
Courtney DiNardo, MD, on Combination Regimens Findings in IDH1-Positive AMLPublished: July 23rd 2020 | Updated:
Courtney DiNardo, MD, on Need for Improved, Effective Regimens in IDH1-Positive AMLPublished: May 31st 2020 | Updated:
Courtney DiNardo, MD, on Next Steps in Combination Regimens to Treat IDH1-Positive AMLPublished: July 30th 2020 | Updated:
Courtney DiNardo, MD, on Looking Forward in AML TreatmentPublished: August 5th 2020 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
This Week in Oncology: FDA Approval Shakeups and Key SITC 2025 Data
2
Atezolizumab/Vaccine Combo May Show Long-Term Survival in ES-SCLC
3
Will Targeting EVA1 With ADCs Eliminate Glioblastoma-Initiating Cells?
4
The Latest and Hottest Topics in ADCs: A Discussion With a Chemical Engineer
5
